Comparative Pharmacology
Head-to-head clinical analysis: PITRESSIN TANNATE versus STIMATE NEEDS NO REFRIGERATION.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PITRESSIN TANNATE versus STIMATE NEEDS NO REFRIGERATION.
PITRESSIN TANNATE vs STIMATE (NEEDS NO REFRIGERATION)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pitressin Tannate is a synthetic form of vasopressin (antidiuretic hormone) that acts on V2 receptors in the renal collecting ducts to increase water reabsorption, and on V1 receptors to cause vasoconstriction.
Desmopressin is a synthetic analogue of vasopressin (antidiuretic hormone) that increases cyclic AMP levels in renal collecting duct cells, enhancing water reabsorption and concentrating urine. It also raises plasma levels of von Willebrand factor and factor VIII by stimulating release from endothelial stores.
0.5-1 mL (5-10 units) intramuscularly or subcutaneously every 24-48 hours as needed for diabetes insipidus.
Intranasal: 1 spray (1.5 mg) into one nostril; may repeat once after 30-60 minutes if needed. Not to exceed 2 doses per bleeding episode.
None Documented
None Documented
Terminal elimination half-life approximately 15 minutes (range 10–20 minutes). Clinically, due to rapid clearance, effects are short-lived; continuous infusion or depot formulations are required for sustained effect.
Terminal elimination half-life is 2-4 hours (mean 3 hours), which supports a dosing interval of 2-4 hours in clinical use.
Primarily renal: >95% of administered dose excreted unchanged in urine within 24 hours. Biliary/fecal elimination negligible (<5%).
Renal excretion of intact drug and metabolites accounts for >90% of elimination; biliary/fecal excretion is minimal (<5%).
Category C
Category C
Antidiuretic Hormone Analog
Antidiuretic Hormone Analog